MULTIPLE MYELOMA IN RELAPSE
Clinical trials for MULTIPLE MYELOMA IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA IN RELAPSE trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to extend remission after second transplant for tough blood cancer
Disease control OngoingThis study is testing whether a three-drug combination (elotuzumab, pomalidomide, and dexamethasone) can help people with multiple myeloma that has returned after their first stem cell transplant. The treatment is given as a long-term 'maintenance' therapy after a second transpla…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 01, 2026 22:41 UTC
-
New drug combo tested for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing a new combination of three drugs (ixazomib, pomalidomide, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to prior treatments. The main goals are to find the safest dose of this combination and to see how well it …
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Omar Nadeem, MD • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Doctors test personalized drug cocktails for Tough-to-Treat blood cancer
Disease control OngoingThis study tests whether doctors can choose effective drug combinations for patients with multiple myeloma that has returned or stopped responding to previous treatments. Eighteen participants will receive one of three different drug combinations based on their doctor's judgment,…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug tested for Tough-to-Treat blood cancer
Disease control OngoingThis is an early-stage study to test the safety of a new drug called HPN217 (or MK-4002) for people with multiple myeloma that has come back or stopped responding to other treatments. Researchers will give increasing doses to about 100 participants to find the highest dose that i…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Can an app empower cancer patients?
Knowledge-focused OngoingThis study is testing whether using a digital health platform called All4Cure helps people with multiple myeloma feel more in control of their health. About 200 participants will fill out surveys over a year to measure their engagement and symptom burden. The goal is to see if th…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Sponsor: All4Cure • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC